If the symptoms of shortness of breath caused by Tegretol are mild and can be tolerated by the patient, the patient can usually continue to take the drug, but the patient must pay attention to the changes in the body; if the symptoms are more serious or the patient cannot tolerate them, the patient most likely cannot continue to take the drug. Tegretol shortness of breath caused by whether to continue to take, and the actual situation of the patient is closely related to the general situation, most of the shortness of breath, the symptoms are relatively mild, the body can also be tolerated, adhere to the medication part of the patient can be relieved on their own, this kind of patients usually can continue to take the drug. However, there are some patients who have severe symptoms that cannot be tolerated by the body, in which case they cannot continue to take the medication. Tegretol is an antiplatelet drug that, in combination with aspirin, is used to treat patients with acute coronary syndromes, a history of myocardial infarction, and at least one other risk factor for atherothrombotic events, and may reduce the incidence of myocardial infarction and stroke, and cardiovascular mortality. Dyspnea, hyperuricemia, bleeding from blood disorders are common side effects of this drug. Tegretol is contraindicated in patients with a history of intracranial hemorrhage, active pathologic bleeding (e.g., intracranial hemorrhage or peptic ulcers), severe hepatic impairment, hypersensitivity to the components of this drug, and with potent CYR3A4 inhibitors such as ketoconazole and clarithromycin. As a prescription drug, Tegretol must be used under medical supervision.